INHIBRX BIOSCIENCES, INC. Adjustments to Additional Paid in Capital, Warrant Issued
INHIBRX BIOSCIENCES, INC. (INBX) reported Adjustments to Additional Paid in Capital, Warrant Issued of $1.29 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2026-03-31 was $1.29M, a 25.06% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2025-03-31 was $1.72M.
- INHIBRX BIOSCIENCES, INC. adjustments to additional paid in capital, warrant issued for fiscal 2025 was $1.72M.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|
| 2026-03-31 | $1.29M 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $1.72M 10-K · filed 2026-03-19 | |
| 2025-03-31 | $1.72M 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |